Knight Therapeutics Announces Launch of JORNAY PM™ in Canada

Core Insights - Knight Therapeutics Inc. has launched JORNAY PM™, an extended-release formulation of methylphenidate for treating ADHD in children aged 6-12 in Canada [1][3][4] Company Overview - Knight Therapeutics Inc. is a pan-American specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products for Canada and Latin America [9][10] - The company has entered into an agreement with Ironshore Pharmaceuticals for exclusive distribution rights of JORNAY PM™ in Canada and Latin America [4] Product Details - JORNAY PM™ is the first evening-dosed methylphenidate product available in Canada, designed to provide therapeutic benefits from morning until evening [7][8] - The product utilizes a unique delayed-release and extended-release technology, allowing for a smooth onset of effect at waking [2][7] - Clinical trials demonstrated significant improvement in ADHD symptom control throughout the day, with common adverse events including insomnia and decreased appetite [8] Market Context - The Canadian ADHD market is valued at approximately $1.25 billion in 2024, with methylphenidates accounting for over $500 million and experiencing a compound annual growth rate (CAGR) of more than 14% over the past four years [5]